Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 4NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 4Sarcoma 2Thoracic 1Lymphoid 1Dermatologic 1

Conditions

Melanoma 284Lymphoma, T-Cell, Cutaneous 108Mycosis Fungoides 83Sezary Syndrome 80Lymphoma, Non-Hodgkin 74Leukemia, Lymphocytic, Chronic, B-Cell 74Lymphoma, Large B-Cell, Diffuse 72Lymphoma, Follicular 71Precursor Cell Lymphoblastic Leukemia-Lymphoma 70Burkitt Lymphoma 68Lymphoma, Mantle-Cell 67Lymphoma, B-Cell, Marginal Zone 67Hodgkin Disease 67Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 65Lymphoma, Large-Cell, Immunoblastic 65Lymphoma, Large-Cell, Anaplastic 62Lymphoma 58Immunoblastic Lymphadenopathy 56Intraocular Lymphoma 43Breast Neoplasms 41Skin Neoplasms 40Neoplasms 37Carcinoma, Renal Cell 35Waldenstrom Macroglobulinemia 33Neoplasm Metastasis 33Uveal Melanoma 29Leukemia, Myeloid, Acute 23Leukemia, Hairy Cell 23Carcinoma, Non-Small-Cell Lung 22Sarcoma 21

Interventions

Cyclophosphamide 1Celecoxib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Neoplasm, Residual × Dermatologic × Clear all
NCT02054104 2022-01-26

Adjuvant Tumor Lysate Vaccine and Iscomatrix With or Without Metronomic Oral Cyclophosphamide and Celecoxib in Patients With Malignancies Involving Lungs, Esophagus, Pleura, or Mediastinum

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
21 enrolled 11 charts
DermatologicSarcoma

Melanoma, Sarcoma, Neoplasm, Residual

Data powered by HemOnc (CC BY 4.0) Colophon âš¡